Aerosol Biology Small Animal Models

气溶胶生物学小动物模型

• 批准号: 7641634
• 负责人: Robert MARK Buller
• 金额: $ 33.87万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-03-01 至 2009-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7641634
• 关键词: Acclimatization; Aerosols; Air; Animal Husbandry; Animal Model; Animals; Bacteria; Basic Science; Biology; Biomedical Research; Biotechnology; Categories; Cells; Clinical Services; Custom; Detection; Disease; Early Intervention; End Point; Generations; Health; Human; Infection; Intervention; Laboratories; Literature; Medical Surveillance; Methods; Modeling; Molecular; Mus; National Institute of Allergy and Infectious Disease; Operative Surgical Procedures; Oryctolagus cuniculus; Particle Size; Pathogenesis; Pathology; Pneumonic Plague; Preclinical Testing; Qualifying; Quarantine; Range; Rattus; Reporting; Research; Research Personnel; Respiratory System; Respiratory Tract Infections; Route; Sampling; Services; Smallpox; Specimen; Techniques; Testing; Therapeutic; Tissues; Virus; Writing; aerosolized; biosafety level 3 facility; design; in vivo; instrumentation; pathogen; prophylactic; respiratory; response; sample collection

The Aerosol Biology/Small Animal Models Core, hereafter referred to as the ABSAM Core or Core, will provide support for smallpox and pneumonic plague research as these diseases will be the most intensely studied NIAID Category A agents in Region 7. Other in vivo pathogen models wil be developed with the judicious selection of consultants, and as the needs arise Although the Core will be capable of infecting animals through a full range of inoculation routes, it will provide exceptional support for the use of respiratory routes of infection. The respiratory tract is the route of infection of the majority of human pathogens and will likely be the target of bioweapons; however, there _s a paucity of information in the scientific literature describing the molecular pathogenesis of NIAID category A, B, and C agents following respiratory tract infections, and the innate and mucosal responses to such infections. The starting point for the study of interactions of pathogens with the respiratory tract is a reproducible and efficient method for mimicking the natural infection. The Core will have expertise to infect animals by the intranasal, intratracheal, and aerosol exposure routes of inoculation. A major focus of the Core will be to provide support for the generation and quantification of aerosols with a wide range of mean aerodynamic particle sizes permitting the delivery of both bacteria and viruses to distinct regions of the respiratory tract. Existing and custom designed instrumentation will be used to support the study of basic questions in pathogenesis following aerosol infection, and to develop specific challenge models for preclinical testing of therapeutics and prophylactics for NIAID category A, B. and C agents. The Core will have the capacity to aerosolize and deliver therapeutics to the respiratory tract for the study of early intervention strategies, and wilt develop and test instrumentation designed to inactivate bioparticles in the air. Additional Core services will include: animal acquisition, quarantine and acclimation, health surveillance, husbandry, specimen collection, surgical services, clinical laboratory sample analysis, pathology services, and report writing. The Core will support studies in Region 7, at other Centers in the RCE network, and those originating from qualified biotechnology companies. Small biotechnology companies may find this Core particularly attractive as they will likely lack BSL-3 facilities, and the required regulatory oversight for using animals in biomedical research (AAALAC, USDA, and PHS). In addition, these companies will typically lack the expertise to carry out in vivo infections, to provide animal husbandry for infected animals, and to perform techniques necessary to acquire specimens for determination of experimental end-points.

气溶胶生物学/小动物模型核心（以下简称ABSAM核心或核心）将提供支持 用于天花和肺鼠疫研究，因为这些疾病将是NIAID A类研究最深入的疾病 7区的特工其他体内病原体模型将通过明智地选择顾问来开发， 虽然核心能够通过各种接种途径感染动物，但它将 为使用呼吸道感染途径提供特殊支持。呼吸道是感染的途径。 大多数人类病原体，并可能成为生物武器的目标;然而，缺乏信息 在描述NIAID A、B和C类药物分子发病机制的科学文献中， 呼吸道感染以及对这种感染的先天和粘膜反应。 研究病原体与呼吸道相互作用的出发点是一种可重复和有效的方法， 模仿自然感染的方法。核心将拥有通过鼻内感染动物的专长， 肠道内接种和气溶胶暴露途径接种。核心小组的一个主要重点是支持 产生和量化具有宽范围的平均空气动力学颗粒尺寸的气溶胶， 细菌和病毒的不同区域的呼吸道。现有和定制设计的仪器 将用于支持气溶胶感染后发病机制中的基本问题的研究，并制定具体的 用于NIAID类别A、B的治疗剂和药物的临床前测试的挑战模型。C特工的 核心将有能力雾化和提供治疗的呼吸道的研究， 他还将开发和测试旨在消除空气中生物颗粒的仪器。 其他核心服务将包括：动物收购、检疫和驯化、健康监测、饲养， 标本采集、手术服务、临床实验室样本分析、病理学服务和报告撰写。 该核心将支持第7区域、RCE网络中的其他中心以及来自合格研究机构的研究。 生物技术公司。小型生物技术公司可能会发现这个核心特别有吸引力，因为他们可能会 缺乏BSL-3设施，以及在生物医学研究中使用动物所需的监管监督（AAALAC，USDA， PHS）。此外，这些公司通常缺乏进行体内感染的专业知识，以提供动物免疫治疗。 饲养受感染的动物，并执行必要的技术，以获取标本，以确定 实验终点